Immunome said on Monday its experimental drug met the main goal in a late-stage study for patients with a rare type of tumor, sending its shares up 25% in morning trade.

Immunome’s investigational oral therapy has slashed the risk of disease progression or death by 84% for patients with desmoid ...

Merck Animal Health announces the availability of Circumvent CL, a ready to use vaccine developed to protect pigs three weeks of age and older from disease caused by Porcine Circovirus Types 2a and 2d ...

The Global Immuno-oncology Clinical Trials Market is expanding steadily due to the rise in cancer incidence, rapid scientific progress in immunotherapy, and growing investments in precision oncology ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ezmekly (mirdametinib) for the treatment of ...

One catalyst happened a couple of weeks ago, when Merck's stock popped by nearly 4% on encouraging clinical data. Let's look ...

By Annette Bakker The tragedy of rare disease is not only measured in lives lost—it’s also measured in lives that could have been saved, if only abandoned discoveries had been given another chance.

Merck & Co Inc. is seeking to raise as much as $8 billion through a corporate bond sale, with part of the proceeds expected to help fund its proposed acquisition of Cidara Therapeutics Inc., according ...

Merck (MRK)’s stock surged by 41% over the past six months, driven not significantly by revenue, but rather by increased profits and heightened investor confidence. Following crucial Q3 earnings ...

With a phase 3 win for a combination of its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) and Keytruda, Merck & Co.’s partner Kelun-Biotech is the latest to claim that ...

Shares of Merck & Company, Inc. (NASDAQ: MRK) are trading higher the FDA approved pembrolizumab with enfortumab vedotin-ejfv for muscle-invasive bladder cancer. MRK shares are powering higher on ...

Partnership includes upfront and potential milestone payments totaling up to over 3 billion dollars LEXINGTON, Mass.--(BUSINESS WIRE)--Valo Health, Inc. (“Valo”), a company pioneering the use of human ...